Atossa Genetics (ATOS)
(Delayed Data from NSDQ)
$1.34 USD
-0.02 (-1.47%)
Updated Jul 19, 2024 03:59 PM ET
After-Market: $1.34 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Price, Consensus and EPS Surprise
ATOS 1.34 -0.02(-1.47%)
Will ATOS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ATOS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ATOS
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?
Are Medical Stocks Lagging Alvotech (ALVO) This Year?
ATOS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?
Atossa Genetics Inc. (ATOS) is a Great Momentum Stock: Should You Buy?
Atossa (ATOS) Reports Positive Results From EVANGELINE Study
Other News for ATOS
Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer
Atossa Therapeutics’ Promising Z-endoxifen Trial Data Backs Analyst’s Buy Recommendation
Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
Atossa announces updated protocol for trial of (Z)-Endoxifen with abemaciclib
Atossa Set to Join Russell 3000® Index Effective June 28, 2024